# NewAmsterdam Pharma

Organization · id `cardio:org-newamsterdam-pharma` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=NewAmsterdam+Pharma>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 10 trials in this atlas.

## Technical summary

Sponsor class industry. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: NewAmsterdam Pharma
- Sponsor class: INDUSTRY

## Connected pages

- Sponsors: Randomized Study of Obicetrapib as an Adjunct to Statin Therapy (`cardio:ct-nct04753606`)
- Sponsors: Randomized Study of Obicetrapib in Combination With Ezetimibe (`cardio:ct-nct04770389`)
- Sponsors: Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (`cardio:ct-nct05142722`)
- Sponsors: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease (`cardio:ct-nct05202509`)
- Sponsors: Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy (`cardio:ct-nct05266586`)
- Sponsors: A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy. (`cardio:ct-nct05421078`)
- Sponsors: Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies. (`cardio:ct-nct05425745`)
- Sponsors: Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies (`cardio:ct-nct06005597`)
- Sponsors: A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque (`cardio:ct-nct06305559`)
- Sponsors: A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome (`cardio:ct-nct07219602`)

## Provenance

Content hash: f0b44816d6d7e667e99069727892bfe0c518f22a97840b9f1cb75cd31a8d799d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
